Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ostfildern – page 22

1 006 clinical trials in Ostfildern, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ostfildern at a glance
1 006
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 006 trials in Ostfildern

Open in trial search

Study Comparing Treosulfan and Melphalan with Fludarabine for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Undergoing Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fludarabine
  • Sponsor:Technische Universitat Dresden

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Bladder cancer

Recruiting

Study of EG-70 for Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to BCG or High-Risk Patients New to BCG or with Incomplete BCG Treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lauromacrogol 400
  • Sponsor:Engene Inc.

Study of TCR-Modified T Cell Therapy with ANOC-001, ANOC-002, and ANOC-003 for Adults with Advanced Pancreatic Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ANOC-001
  • Sponsor:Anocca AB

Breast cancer+1

Recruiting

A Study of Trastuzumab Deruxtecan Treatment for Patients with Early-Stage HER2-Positive or HER2-Low Breast Cancer Who Show Signs of Molecular Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Universitaetsklinikum Ulm AöR

Evaluation of Cemiplimab Safety and Effectiveness as First Treatment for Advanced Basal Cell Carcinoma in Adult Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study of durvalumab with chemotherapy (paclitaxel, cisplatin, carboplatin, vinorelbine) in patients with stage IIIA/B non-small cell lung cancer that can be removed by surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Study on Reducing Acute Kidney Injury After Heart Surgery Using Angiotensin II or Noradrenaline for Patients with Low Blood Pressure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Angiotensin II
  • Sponsor:Universitaet Muenster

Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Vulval cancer

Recruiting

Study of Pembrolizumab and Lenvatinib for Patients with Advanced Vulvar Cancer Not Suitable for Surgery or Radiotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:AGO Research GmbH

Study of DNAJB1-PRKACA Peptide Vaccine for Patients with Fibrolamellar Hepatocellular Carcinoma and Other Tumors with Oncogenic Driver Fusion

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:DNAJB1-PRKACA TRIFLUORACETATE
  • Sponsor:Universitaetsklinikum Tuebingen AöR

Study on the Safety of Self-Infusion Therapy with Human Alpha1-Proteinase Inhibitor for Patients with Severe Alpha-1 Antitrypsin Deficiency

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ALPHA-1-ANTITRYPSIN
  • Sponsor:Grifols S.A.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Ostfildern

What the registry says about research in the country

01 Colorectal Cancer Research

Innovative studies focusing on pre-operative treatment and advanced therapeutic approaches for patients with colorectal cancer, including investigations of new combination therapies.

  • Advanced colon cancer treatment protocols
  • Metastatic colorectal carcinoma therapy
  • Stage II colon cancer management

These trials aim to improve treatment outcomes through systematic therapy optimization.

02 Gastric Cancer Studies

Research focusing on advanced gastric adenocarcinoma treatment, particularly examining second-line therapy options for patients who have undergone prior treatment.

  • Combination therapy assessment
  • Treatment response evaluation
  • Survival outcome analysis

Investigating innovative therapeutic combinations to enhance patient outcomes.

03 Supportive Care Research

Studies addressing chemotherapy-induced complications, including prevention and management of polyneuropathy in cancer patients undergoing treatment.

  • CIPN prevention strategies
  • Quality of life improvement
  • Symptom management

Focus on reducing treatment-related side effects and improving patient comfort.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.